Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$942.00K$942.00K−35.7% vs Q1 2017 Net Income-$19.93M-$19.93MN/M vs Q1 2017 EPS Diluted-$0.63-$0.63N/M vs Q1 2017 Operating Income-$21,093,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
Free Cash Flowderived$47,003,000N/M Margins · derivedOperating margin-2239.2%−1042.3 pt vs Q1 2017
Net margin-2115.3%−978.1 pt vs Q1 2017
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end